Developer docs
API playgroundTry for free, no card

Search company profiles

iGan Partners

Full company profile

uuid0000hkh

Namestring
iGan Partners
Legal namestring
iGan Partners
Company typeenum
Private
Founded yearint
2013
Descriptiontext

iGan Partners is a Toronto-based venture capital firm founded in 2013 (with a first recorded portfolio investment in 2012) that invests at seed through Series A in AI-enabled MedTech and Digital Health companies. The firm is led by Founder & Managing Partner Sam Ifergan, with Dr. Lorena Tora serving as Chief Medical Officer and a small operator-investor team of 11-50 staff based at 60 Bloor Street West. Its 20+ portfolio companies include medical devices (ExactVu micro-ultrasound, MolecuLight fluorescence wound imaging, FloPatch wearable Doppler, eSight vision enhancement, Adenocyte LINFU), AI diagnostics (RetiSpec for Alzheimer's, Cosm Medical for women's health), data platforms (Segmed, Marble SettLiT), and confidential AI infrastructure (CyborgDB).

The firm's core technology proposition is not a product but a curated investment platform combining smart-capital with active portfolio support, domain-specific medical expertise, and access to a syndicate network of co-investors and industry partners. Portfolio companies deploy AI/ML in modalities including computer vision (MolecuLight, eSight, ExactVu), NLP-based PHI de-identification (Segmed on OpenAI's davinci), predictive analytics on retinal imagery (RetiSpec), and encrypted vector inference (CyborgDB).

iGan generates revenue primarily through management fees on its funds and carried interest from exits. The flagship Canadian/US fund is supplemented by the US$250M iGan Arabia regional fund launched in October 2022 with Faisal Belhoul to invest across the Middle East and North Africa. Distribution channels include a website pitch portal, direct founder outreach, industry referrals, the annual Pitch to Heal competition (awarding $600K), and strategic partnerships with Medical Alley (US pipeline), St. Andrews Medical Center and Previta (Mexico), and Quest Diagnostics (commercial lab access for portfolio products). The firm has documented at least one major exit (eSight acquired by Gentex in January 2024) and is actively deploying capital through 2025-2026.

Short descriptiontext

iGan Partners is a Toronto-based venture capital firm founded in 2013 that invests at seed through Series A in AI-enabled MedTech and Digital Health companies in Canada, the US, and MENA. It supports 20+ portfolio companies with smart-capital, operator mentorship, and an industry co-investor network, and runs the US$250M iGan Arabia fund.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, medical device investment, digital health investing, seed stage funding, MedTech startup funding
Industry3 codes
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANAJAN
SDG / Thematic Sustainable Investment Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
SECONDARYFSANAAAE
Geography-Focused Venture Capital (Regional/Emerging Markets)
NAICS code3 codes
  • Portfolio Management and Investment Advice52394
  • All Other Financial Investment Activities52399
  • Miscellaneous Financial Investment Activities523999
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Venture Capital
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns
TypeLicensing Royalties
Description

iGan Partners generates returns through capital appreciation and exits from portfolio companies. Returns come from IPOs, acquisitions, and secondary transactions. The firm has had successful exits including Fujifilm Visualsonics (IPO) and eSight (acquired by Gentex).

iganpartners.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

iGan Partners is a Canadian venture capital firm that invests seed and Series A capital in early-stage companies commercializing AI-enabled MedTech and Digital Health technologies. The firm provides portfolio companies with smart-capital, active support, and access to a network of industry partners and sector-specific co-investors to help them grow and achieve successful exits, including IPOs and strategic acquisitions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Multiple successful exits including Fujifilm Visualsonics (IPO) and eSight (acquired by Gentex)
+1 more record
Product overview1 text field

iGan Partners is a healthcare-focused venture capital firm that provides capital, active support, and access to a network of industry partners and sector-specific co-investors to early-stage companies in AI-enabled MedTech and Digital Health. iGan Partners does not offer its own proprietary product or service; rather, it supports portfolio companies that develop and commercialize distinct healthcare technology products. The portfolio includes medical devices (ExactVu micro-ultrasound system, MolecuLight i:X/DX fluorescence imaging devices, FloPatch wearable ultrasound, eSight Go vision enhancement glasses, Adenocyte LINFU system), AI diagnostics (RetiSpec AI eye test for Alzheimer's detection, Gynethotics AI-driven personalized gynecological devices), data platforms (Segmed medical imaging data platform, Marble SettLiT health data integration product), and AI infrastructure (CyborgDB confidential computing platform). These portfolio products address applications in cancer detection, wound care, hemodynamic monitoring, vision assistance, women's health, and healthcare data management.

Product and service3 records
1Seed-Stage Venture Capital Investment
CategoryVenture Capital Investment
Description

Equity capital and active support provided to early-stage healthcare startups from inception, including deal structure guidance and lead investment through every subsequent financing round.

2iGan Arabia Regional Fund
CategoryVenture Capital Fund
Description

US$250 million regional venture capital fund targeting AI/Cloud-enhanced medical devices and digital health technologies across the Middle East and North Africa (MENA) region, launched in partnership with Faisal Belhoul.

3Pitch to Heal Competition
CategoryDeal Sourcing Program
Description

Annual competition awarding $600k investment to Canadian healthcare startups, held at Four Seasons Hotel in Toronto with over 200 attendees from the Canadian and international healthcare community.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-26
Description

National laboratory services partnership for processing LINFU enhanced pancreatic cytology samples at Quest and AmeriPath laboratories in Tampa, Florida. Supports commercial expansion of Adenocyte's pancreatic cancer early detection platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-10
Description

Strategic partnership between iGan Partners and Medical Alley to accelerate development and adoption of pioneering medtech solutions. iGan Partners will work with Medical Alley Starts to identify, support, and scale innovative medical devices and digital health organizations. The partnership focuses on driving growth and scaling breakthrough technologies in healthcare through cross-border collaborations.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2024-09-10
Description

Venture platform under Medical Alley that accelerates formation and growth of startups. Partnership provides iGan Partners with early access to promising startup pipeline while providing portfolio companies with exceptional resources and strategic guidance.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-21
Description

First entirely American medical center in Mexico, dedicated to implementing value-based healthcare and clinical evidence-based medical technology. Will dedicate space within facility for testing advanced medical devices and software to accelerate clinical trials and innovative healthcare deployments in Mexico, Canada, and US.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-21
Description

Mexico's largest home healthcare services provider, joining forces to deliver high-quality healthcare services to patients' homes and hospitals via remote monitoring. Partnership aims to bridge gap in quality healthcare by leveraging preventive and treatment services combined with innovative technologies.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Optum's venture arm investing in healthcare and digital health startups. Larger and more established than iGan with strategic backing from UnitedHealth Group, but both focus on healthcare innovation at the growth stage.

TypeBroad incumbent
Description

Major US venture firm with dedicated healthcare and bio fund investing across stages. Substantially larger AUM than iGan with overlapping interest in AI-enabled healthcare and digital health, but operates at Series A and beyond rather than seed-stage Canadian focus.

TypeDirect peer
Description

Healthcare-focused venture fund investing in early-stage companies across digital health, medical devices, and AI diagnostics. Direct comparable in vertical specialization and stage focus, though US-based rather than Canadian.

TypeBroad incumbent
Description

Long-standing healthcare and biotech venture firm with deep expertise in early-stage healthcare investing. Comparable in sector specialization but typically operates at larger check sizes and later stages than iGan.

TypeDirect peer
Description

Healthcare-focused investment firm with both public and private equity strategies. Overlaps with iGan in clinical-stage healthcare investing but operates at larger scale and across both public and private markets.

TypeBroad incumbent
Description

Tech and science-focused VC with significant healthcare investing. Comparable interest in healthcare AI and frontier tech, though broader sector mandate than iGan's pure healthcare focus.

TypeBroad incumbent
Description

Major US VC with significant healthcare and digital health investments alongside broader tech focus. Larger scale than iGan with overlapping thesis on AI-enabled healthcare transformation.

TypeBroad incumbent
Description

Large venture firm with a dedicated healthcare practice (Health Assurance) and significant digital health portfolio. Comparable healthcare focus but operates at much larger scale across multiple stages.

TypeDirect peer
Description

Comparable early-stage healthcare VCs include ARTIS Ventures, Civilization Ventures, and Health Catalyst Capital — firms that invest at seed/Series A in healthcare AI and digital health, similar stage and vertical focus as iGan Partners.

TypeRegional player
Description

Toronto-based innovation hub supporting healthcare and tech startups with venture services. Regional comparable to iGan's Canadian healthcare startup ecosystem focus, though operates as an innovation hub rather than a dedicated VC fund.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability15 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment46 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

iGan Partners

Healthcare Venture Capitaliganpartners.com

iGan Partners is a Toronto-based venture capital firm founded in 2013 that invests at seed through Series A in AI-enabled MedTech and Digital Health companies in Canada, the US, and MENA. It supports 20+ portfolio companies with smart-capital, operator mentorship, and an industry co-investor network, and runs the US$250M iGan Arabia fund.

What iGan Partners does

iGan Partners is a Toronto-based venture capital firm founded in 2013 (with a first recorded portfolio investment in 2012) that invests at seed through Series A in AI-enabled MedTech and Digital Health companies. The firm is led by Founder & Managing Partner Sam Ifergan, with Dr. Lorena Tora serving as Chief Medical Officer and a small operator-investor team of 11-50 staff based at 60 Bloor Street West. Its 20+ portfolio companies include medical devices (ExactVu micro-ultrasound, MolecuLight fluorescence wound imaging, FloPatch wearable Doppler, eSight vision enhancement, Adenocyte LINFU), AI diagnostics (RetiSpec for Alzheimer's, Cosm Medical for women's health), data platforms (Segmed, Marble SettLiT), and confidential AI infrastructure (CyborgDB).

The firm's core technology proposition is not a product but a curated investment platform combining smart-capital with active portfolio support, domain-specific medical expertise, and access to a syndicate network of co-investors and industry partners. Portfolio companies deploy AI/ML in modalities including computer vision (MolecuLight, eSight, ExactVu), NLP-based PHI de-identification (Segmed on OpenAI's davinci), predictive analytics on retinal imagery (RetiSpec), and encrypted vector inference (CyborgDB).

iGan generates revenue primarily through management fees on its funds and carried interest from exits. The flagship Canadian/US fund is supplemented by the US$250M iGan Arabia regional fund launched in October 2022 with Faisal Belhoul to invest across the Middle East and North Africa. Distribution channels include a website pitch portal, direct founder outreach, industry referrals, the annual Pitch to Heal competition (awarding $600K), and strategic partnerships with Medical Alley (US pipeline), St. Andrews Medical Center and Previta (Mexico), and Quest Diagnostics (commercial lab access for portfolio products). The firm has documented at least one major exit (eSight acquired by Gentex in January 2024) and is actively deploying capital through 2025-2026.

iGan Partners firmographics

Firmographics
Name
iGan Partners
Legal name
iGan Partners
Website
https://iganpartners.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
iGan Partners is a Toronto-based venture capital firm founded in 2013 that invests at seed through Series A in AI-enabled MedTech and Digital Health companies in Canada, the US, and MENA. It supports 20+ portfolio companies with smart-capital, operator mentorship, and an industry co-investor network, and runs the US$250M iGan Arabia fund.
Ownership category
akta.pro rank

iGan Partners industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
Portfolio Management and Investment Advice (52394), All Other Financial Investment Activities (52399), Miscellaneous Financial Investment Activities (523999)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANAJAN
SDG / Thematic Sustainable Investment Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
SECONDARYFSANAAAE
Geography-Focused Venture Capital (Regional/Emerging Markets)

Keywords

  • Healthcare venture capital
  • Medical device investment
  • Digital health investing
  • Seed stage funding
  • MedTech startup funding

Where iGan Partners is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

iGan Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Investment Returns: iGan Partners generates returns through capital appreciation and exits from portfolio companies. Returns come from IPOs, acquisitions, and secondary transactions. The firm has had successful exits including Fujifilm Visualsonics (IPO) and eSight (acquired by Gentex).

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

iGan Partners product offering

Product offering

Core offering

iGan Partners is a Canadian venture capital firm that invests seed and Series A capital in early-stage companies commercializing AI-enabled MedTech and Digital Health technologies. The firm provides portfolio companies with smart-capital, active support, and access to a network of industry partners and sector-specific co-investors to help them grow and achieve successful exits, including IPOs and strategic acquisitions.

Product overview

iGan Partners is a healthcare-focused venture capital firm that provides capital, active support, and access to a network of industry partners and sector-specific co-investors to early-stage companies in AI-enabled MedTech and Digital Health. iGan Partners does not offer its own proprietary product or service; rather, it supports portfolio companies that develop and commercialize distinct healthcare technology products. The portfolio includes medical devices (ExactVu micro-ultrasound system, MolecuLight i:X/DX fluorescence imaging devices, FloPatch wearable ultrasound, eSight Go vision enhancement glasses, Adenocyte LINFU system), AI diagnostics (RetiSpec AI eye test for Alzheimer's detection, Gynethotics AI-driven personalized gynecological devices), data platforms (Segmed medical imaging data platform, Marble SettLiT health data integration product), and AI infrastructure (CyborgDB confidential computing platform). These portfolio products address applications in cancer detection, wound care, hemodynamic monitoring, vision assistance, women's health, and healthcare data management.

Differentiator

Problem solved

Functional benefit

Products and services

  • Seed-Stage Venture Capital Investment Equity capital and active support provided to early-stage healthcare startups from inception, including deal structure guidance and lead investment through every subsequent financing round.
  • iGan Arabia Regional Fund US$250 million regional venture capital fund targeting AI/Cloud-enhanced medical devices and digital health technologies across the Middle East and North Africa (MENA) region, launched in partnership with Faisal Belhoul.
  • Pitch to Heal Competition Annual competition awarding $600k investment to Canadian healthcare startups, held at Four Seasons Hotel in Toronto with over 200 attendees from the Canadian and international healthcare community.

Quantifiable outcome

  • Multiple successful exits including Fujifilm Visualsonics (IPO) and eSight (acquired by Gentex)
  • +1 more outcomes

Companies that use iGan Partners

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles1 record

iGan Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability15 records

iGan Partners partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered major and core.

  • Quest DiagnosticsmajorChannel Partner/ Reseller/ Distributor · 26 May 2026National laboratory services partnership for processing LINFU enhanced pancreatic cytology samples at Quest and AmeriPath laboratories in Tampa, Florida. Supports commercial expansion of Adenocyte's pancreatic cancer early detection platform.
  • Medical AlleycoreStrategic or Co-development Partner · 10 September 2024Strategic partnership between iGan Partners and Medical Alley to accelerate development and adoption of pioneering medtech solutions. iGan Partners will work with Medical Alley Starts to identify, support, and scale innovative medical devices and digital health organizations. The partnership focuses on driving growth and scaling breakthrough technologies in healthcare through cross-border collaborations.
  • Medical Alley StartscoreGTM or Marketing Partner · 10 September 2024Venture platform under Medical Alley that accelerates formation and growth of startups. Partnership provides iGan Partners with early access to promising startup pipeline while providing portfolio companies with exceptional resources and strategic guidance.
  • St. Andrews Medical CentercoreStrategic or Co-development Partner · 21 September 2023First entirely American medical center in Mexico, dedicated to implementing value-based healthcare and clinical evidence-based medical technology. Will dedicate space within facility for testing advanced medical devices and software to accelerate clinical trials and innovative healthcare deployments in Mexico, Canada, and US.
  • PrevitacoreStrategic or Co-development Partner · 21 September 2023Mexico's largest home healthcare services provider, joining forces to deliver high-quality healthcare services to patients' homes and hospitals via remote monitoring. Partnership aims to bridge gap in quality healthcare by leveraging preventive and treatment services combined with innovative technologies.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

iGan Partners competitors and assessment

Company assessment

Broad incumbents

  • Optum Ventures: Optum's venture arm investing in healthcare and digital health startups. Larger and more established than iGan with strategic backing from UnitedHealth Group, but both focus on healthcare innovation at the growth stage.
  • Andreessen Horowitz Bio Fund: Major US venture firm with dedicated healthcare and bio fund investing across stages. Substantially larger AUM than iGan with overlapping interest in AI-enabled healthcare and digital health, but operates at Series A and beyond rather than seed-stage Canadian focus.
  • ARCH Venture Partners: Long-standing healthcare and biotech venture firm with deep expertise in early-stage healthcare investing. Comparable in sector specialization but typically operates at larger check sizes and later stages than iGan.
  • Lux Capital: Tech and science-focused VC with significant healthcare investing. Comparable interest in healthcare AI and frontier tech, though broader sector mandate than iGan's pure healthcare focus.
  • Khosla Ventures: Major US VC with significant healthcare and digital health investments alongside broader tech focus. Larger scale than iGan with overlapping thesis on AI-enabled healthcare transformation.
  • General Catalyst: Large venture firm with a dedicated healthcare practice (Health Assurance) and significant digital health portfolio. Comparable healthcare focus but operates at much larger scale across multiple stages.

Direct peers

  • Section32: Healthcare-focused venture fund investing in early-stage companies across digital health, medical devices, and AI diagnostics. Direct comparable in vertical specialization and stage focus, though US-based rather than Canadian.
  • RA Capital Management: Healthcare-focused investment firm with both public and private equity strategies. Overlaps with iGan in clinical-stage healthcare investing but operates at larger scale and across both public and private markets.
  • Early Stage Healthcare VCs (Seed-Series A focus): Comparable early-stage healthcare VCs include ARTIS Ventures, Civilization Ventures, and Health Catalyst Capital — firms that invest at seed/Series A in healthcare AI and digital health, similar stage and vertical focus as iGan Partners.

Regional players

  • MaRS Discovery District: Toronto-based innovation hub supporting healthcare and tech startups with venture services. Regional comparable to iGan's Canadian healthcare startup ecosystem focus, though operates as an innovation hub rather than a dedicated VC fund.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

iGan Partners social profiles

Digital presence

iGan Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

iGan Partners leadership team

Management profile

Number of profiles

Profiles7 records

iGan Partners funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

iGan Partners M&A and investment

M&A and investment

M&A

Investments46 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iGan Partners

What does iGan Partners do?

iGan Partners is a Canadian venture capital firm that invests seed and Series A capital in early-stage companies commercializing AI-enabled MedTech and Digital Health technologies. The firm provides portfolio companies with smart-capital, active support, and access to a network of industry partners and sector-specific co-investors to help them grow and achieve successful exits, including IPOs and strategic acquisitions.

Is iGan Partners a public or private company?

iGan Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was iGan Partners founded?

iGan Partners was founded in 2013. It employs 11 to 50 people.

Where is iGan Partners based?

iGan Partners is headquartered in Toronto, Canada, in the North America region.

How does iGan Partners make money?

One revenue line is on record: investment Returns.

Who are iGan Partners's main competitors?

Broad incumbents on record are Optum Ventures, Andreessen Horowitz Bio Fund, ARCH Venture Partners, Lux Capital, Khosla Ventures and General Catalyst. Direct peers are Section32, RA Capital Management and Early Stage Healthcare VCs (Seed-Series A focus). MaRS Discovery District is listed as a regional player.

Does iGan Partners have an API?

No public API is recorded for iGan Partners.

What industry is iGan Partners in?

iGan Partners's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANAJAN, SDG / Thematic Sustainable Investment Funds. Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestThe Innovation You Can't Own, and the Public Medtech Sector That Buys It AnywayiGan Partners' portfolio update highlights private medtech milestones, including a $70M government contract for Flosonics and 166% revenue growth for Exact Imaging. The public IHI ETF is down 18% year-to-date, while medtech M&A reached $36.5B in H1 2026. The article argues private innovation is accelerating while public earnings pressure persists.PR NewswireiGan Partners Portfolio Update: Momentum Across Medtech and Health DataiGan Partners reported portfolio milestones, including Flosonics' $70 million BARDA contract for its FloPredict AI software and Exact Imaging's 166% year-over-year revenue growth. MolecuLight published a clinical study on fluorescence imaging in orthopaedic surgery, and Cosm Medical entered a licensing deal with Duke Health and Mayo Clinic.MorningstariGan Partners Portfolio Update: Momentum Across Medtech and Health DataiGan Partners reported portfolio milestones, including Flosonics' $70 million BARDA contract for its FloPredict AI software and Exact Imaging's 166% year-over-year revenue growth. Other updates include MolecuLight's first orthopaedic surgery study and Cosm Medical's licensing deal with Duke Health and Mayo Clinic.Pulse 2.0Adenocyte: $10 Million Financing Raised To Advance Early Detection Of Pancreatic CancerAdenocyte announced the first close of a $10 million financing round led by iGan Partners to advance its pancreatic cancer early detection platform LINFU, which has already entered clinical use at multiple U.S. endoscopy centers with over 150 patient procedures completed successfully. The LINFU system demonstrated 100% specimen adequacy and specificity in its first 90 high-risk asymptomatic patients, detecting four previously unsuspected neoplasia cases including a T1N0 adenocarcinoma that standard methods (EUS, MRI, FNA) failed to identify. The company has also established a collaboration with Quest Diagnostics for national laboratory services as commercial expansion efforts prepare to ramp up through 2026.NewswireiGan Partners Invests in Adenocyte Ltd to Advance the Early Detection of Pancreatic CanceriGan Partners led a $10M financing round in Adenocyte, a medical technology company developing LINFU for early pancreatic cancer detection. The 30-minute outpatient procedure is FDA-cleared and reimbursed by Medicare and commercial insurance, with over 150 patient procedures completed. Proceeds will support clinical and commercial expansion.PR NewswireiGan Partners Invests in Adenocyte Ltd to Advance the Early Detection of Pancreatic CanceriGan Partners led a $10M financing round in Adenocyte, a medical technology company developing LINFU for early pancreatic cancer detection. The 30-minute outpatient procedure is FDA-cleared and reimbursed by Medicare and commercial insurance, with over 150 patient procedures completed. The company plans to expand commercial use in 2026.FinSMEsAdenocyte Receives Investment From iGan PartnersAdenocyte, an Israeli medical technology company, received an undisclosed investment from iGan Partners. The funds will support clinical and commercial expansion and technical development of its LINFU platform for cytological sampling of the pancreas, breast, and prostate. The company aims to use the investment for continued development of its proprietary technology.PR NewswireiGan Partners Leads $10 Million Financing of Exact Imaging, the World's Leading Prostate Cancer Detection PlatformExact Imaging, a Toronto-based developer of high-resolution micro-ultrasound systems for prostate cancer detection, has closed a $10 million financing round led by healthcare-focused investment firm iGan Partners. The proceeds will accelerate global sales and adoption of the company's ExactVu™ prostate biopsy system, which demonstrated non-inferiority to MRI-fusion biopsy in the landmark OPTIMUM study published in JAMA. The company reported record system sales in 2025 following expansion into North America, Europe, Japan, South Korea, Taiwan, Brazil, and Mexico, positioning it to continue doubling sales in 2026.BioSpaceiGan Partners Leads $10 Million Financing of Exact Imaging, the World’s Leading Prostate Cancer Detection PlatformExact Imaging, a Toronto-based leader in high-resolution micro-ultrasound for prostate cancer detection, closed a $10 million financing round led by iGan Partners to accelerate global sales of its ExactVu™ prostate biopsy system. The company reported record system sales in 2025 driven by clinical validation of its OPTIMUM study published in JAMA and expansion into multiple international markets including Europe, Japan, South Korea, Taiwan, Brazil, and Mexico. With this capital, Exact Imaging aims to continue doubling sales in 2026 as it scales its commercial footprint worldwide.NewswireiGan Partners Leads $10 Million Financing of Exact Imaging, the World's Leading Prostate Cancer Detection PlatformExact Imaging announced the closing of a $10 million financing round led by iGan Partners to accelerate global sales and adoption of its ExactVu™ prostate biopsy system. The company published its landmark OPTIMUM study in JAMA, demonstrating that ExactVu™ micro-ultrasound is non-inferior to MRI-fusion biopsy for prostate cancer detection. Exact Imaging also expanded commercial operations across Europe, Japan, South Korea, Taiwan, Brazil, and Mexico, driving record system sales in 2025 with plans to continue doubling sales in 2026.